Moreover, we show that the Cell Marker Accordion can be used to identify pathological processes and disease-critical cells: leukemia cell subtypes, including therapy-resistant cells, in acute myeloid leukemia patients20,21; neoplastic plasma cells in multiple myeloma samples22,23; malignant subpopulations in glioblastoma and lung adenocarcinoma patients24,25; cell type alterations driven by pathologically relevant mutations in myelodysplastic syndromes26,27; activation of innate immunity pathways in bone marrow from mice with Mettl3 deletion or treated with METTL3 inhibitors28,29. This evidence concerns the gene METTL3 and leukemia.